 |
市場調査レポート
商品コード
1452786
ペット用がん治療薬の世界市場規模、シェア、成長分析、治療法別、動物別、用途別 - 産業予測（2024～2031年）Global Pet Cancer Therapeutics Market Size, Share, Growth Analysis, By Therapy(Chemotherapy, Radiation therapy), By Animal(Dogs, Cats), By Application(Lymphoma, Mast Cell Cancer) - Industry Forecast 2024-2031 |
||||||
| ペット用がん治療薬の世界市場規模、シェア、成長分析、治療法別、動物別、用途別 - 産業予測（2024～2031年） |
|
出版日: 2024年03月09日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
ペット用がん治療薬の世界市場規模は、2022年に2億7,391万米ドルと評価され、2023年の3億240万米ドルから2031年には6億6,731万米ドルに成長し、予測期間中（2024-2031年）のCAGRは10.4％で成長する見通しです。
ペット用がん治療薬の世界市場は、ペット医療という広範な領域で注目度と革新性が著しく急上昇しています。飼い主がペットの健康をより重視するようになったことで、ペットに対する効果的ながん治療の選択肢に対する需要が高まっています。この傾向は、ペットの健康に対する意識の高まりと、ペットに最適なケアを提供したいという願望に後押しされています。市場関係者は、ペットに特化した新しい治療薬を開発することでこれに対応し、がんと診断された動物の治療成績の向上と生活の質の改善に期待を寄せています。さらに、獣医腫瘍学の進歩により、ペットのがんに対する理解が深まり、標的療法の開発が促進されています。全体として、ペット用がん治療薬市場は、最愛のペットである動物の特有の医療ニーズに対応する、思いやりと科学的進歩が融合したダイナミックな市場です。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- セカンダリおよびプライマリデータソース
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主な投資の分析
- 主な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
ペット用がん治療薬の世界市場：治療法別
- 市場概要
- 化学療法
- 放射線治療
- 免疫療法
- 標的療法
- その他の治療法
ペット用がん治療薬の世界市場：動物別
- 市場概要
- 犬
- 猫
- その他の動物
ペット用がん治療薬の世界市場：用途別
- 市場概要
- リンパ腫
- 肥満細胞がん
- 黒色腫
- 乳房
- 扁平上皮がん
- その他の用途
ペット用がん治療薬の世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
- 中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Aratana Therapeutics（US）
- Elanco Animal Health（US）
- Vetivax（US）
- Anivive Lifesciences（US）
- Regeneus（Australia）
- Qbiotics（Australia）
- Zoetis（US）
- VetDC（US）
- AB Science（France）
- Merial（France）
- VET Therapeutics（US）
- Vet Cancer Group（US）
- VetriScience（US）
- Vetnostics（Australia）
- Veterinary Cancer Group（US）
- PetCure Oncology（US）
- Veterinary Cancer Society（US）
- PetCure Oncology（US）
- Oasmia Pharmaceutical（Sweden）
Global Pet Cancer Therapeutics Market size was valued at USD 273.91 million in 2022 and is poised to grow from USD 302.40 million in 2023 to USD 667.31 million by 2031, growing at a CAGR of 10.4% during the forecast period (2024-2031).
The global market for pet cancer therapeutics is experiencing a significant surge in attention and innovation within the broader realm of pet healthcare. With pet owners placing greater emphasis on the well-being of their animal companions, the demand for effective cancer treatment options for pets has risen. This trend is fueled by an increasing awareness of pet health and the desire to provide optimal care for pets. Market players are responding by developing new therapeutics specifically tailored to pets, offering hope for enhanced outcomes and improved quality of life for animals diagnosed with cancer. Furthermore, advancements in veterinary oncology are contributing to a deeper understanding of cancer in pets, facilitating the development of targeted therapies. Overall, the pet cancer therapeutics market represents a dynamic landscape where compassion and scientific advancement converge to address the distinctive healthcare needs of beloved animal companions.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pet Cancer Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Pet Cancer Therapeutics Market Segmental Analysis
The global pet cancer therapeutics market is segmented into four segments therapy, animal, application and region. Based on therapy the market is segmented as, chemotherapy, radiation therapy, immunotherapy, targeted therapy, and other therapies. Based on animal, the market is bifurcated as, dogs, cats, other animals. On the basis of application the market is segmented as, lymphoma, mast cell cancer, melanoma, mammary, and squamous cell cancer, other applications. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Drivers of the Global Pet Cancer Therapeutics Market
The burgeoning global pet cancer therapeutics market is significantly fueled by the rising phenomenon of pet humanization, wherein pet owners increasingly perceive their furry companions as indispensable family members. This shift in perspective drives a notable surge in investments towards advanced healthcare solutions, particularly cancer treatments, for pets. Consequently, there's a heightened demand for compassionate and efficacious cancer therapeutics specifically designed for pets, fostering innovation and expansion within the market.
Restraints in the Global Pet Cancer Therapeutics Market
A major obstacle in the worldwide pet cancer therapeutics sector is the exorbitant expense tied to cancer care for pets, covering diagnostics, surgeries, radiation therapy, and medication. These costs can impose significant financial strain on pet guardians, restricting access to advanced cancer treatments and forcing them to make tough decisions regarding their pets' care options. Consequently, despite the growing demand and awareness surrounding pet cancer therapeutics, affordability emerges as a pivotal concern, influencing market dynamics and the accessibility of these treatments.
Market Trends of the Global Pet Cancer Therapeutics Market
A notable trend in the global market for pet cancer therapeutics is the increasing focus on personalized treatment strategies, acknowledging the individuality of each pet's cancer diagnosis and therapeutic needs. This emphasis is fueling the need for customized therapeutic options, encompassing precision medicine and targeted therapies, as well as advancements in diagnostic techniques like genetic profiling and molecular testing. As a result, treatment regimens can be tailored to the unique features of a pet's cancer, enhancing treatment effectiveness and possibly minimizing adverse effects. This transition towards personalized care underscores a rising dedication to improving the standard of care and outcomes for pets grappling with cancer.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Pet Cancer Therapeutics Market by Therapy
- Market Overview
- Chemotherapy
- Radiation therapy
- Immunotherapy
- Targeted Therapy
- and Other Therapies
Global Pet Cancer Therapeutics Market by Animal
- Market Overview
- Dogs
- Cats
- Other Animals
Global Pet Cancer Therapeutics Market by Application
- Market Overview
- Lymphoma
- Mast Cell Cancer
- Melanoma
- Mammary
- and Squamous Cell Cancer
- Other Applications
Global Pet Cancer Therapeutics Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Aratana Therapeutics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Elanco Animal Health (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Vetivax (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Anivive Lifesciences (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Regeneus (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Qbiotics (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zoetis (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- VetDC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AB Science (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merial (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- VET Therapeutics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Vet Cancer Group (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- VetriScience (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Vetnostics (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Veterinary Cancer Group (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PetCure Oncology (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Veterinary Cancer Society (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PetCure Oncology (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Oasmia Pharmaceutical (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
